Solriamfetol 150 mg Clinical Trials
2 recruitingDrug
Phase 32
Showing 1–2 of 2 trials
Recruiting
Phase 3
Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
Binge-Eating Disorder
Axsome Therapeutics, Inc.450 enrolled45 locationsNCT06413433
Recruiting
Phase 3
Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)
Shift-work DisorderExcessive Sleepiness
Axsome Therapeutics, Inc.520 enrolled40 locationsNCT06568367